论文部分内容阅读
【目的】观察单唾液酸四己糖神经节苷脂联合依达拉奉对急性颅脑损伤患者脑保护作用。【方法】将80例急性中重度颅脑损伤患者随机分为观察组和对照组，每组各40例，两组均接受神经外科常规治疗，对照组患者给予依达拉奉治疗，观察组患者在对照组的基础上加用神经节苷脂钠治疗，两组均治疗2周；检测治疗前、治疗后3 d、1周、2周的血清 C 反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、降钙素基因相关肽(CGRP)及神经肽 Y (NPY)，神经元特异性烯醇化酶(NSE)水平，并记录患者治疗后3个月的格拉斯哥预后量表评分(GOS)等级情况。【结果】两组患者血清 TNF-α、CRP 及 NPY 在治疗后3 d、1周、2周均较治疗前降低(P <0.05)，但观察组血清 TNF-α、CRP 及 NPY 在治疗后3 d、1周、2周低于对照组(P <0.05)；两组 CGRP 水平则较治疗前升高(P <0.05)；观察组患者治疗后 NSE 水平亦显著低于对照组(P <0.05)；观察组 CGRP 高于对照组(P <0.05)；观察组治疗后3个月的 GOS 评分中的预后较好率(90.0%)明显高于对照组(72.5%)(χ2=4.021；P =0.045)。【结论】单唾液酸四己糖神经节苷脂联合依达拉奉能够有效降低急性颅脑损伤患者的血清 TNF-α、CRP 及 NPY水平，提高 CGRP 含量，具有较好的脑保护作用，进而改善患者的预后。“,”Objective]To observe the brain-protective effect of monosialoteterahexosyl ganglioside combined with edaravone in acute brain injury.[Methods]80 cases of acute moderate-severe brain injury patients were ran-domly divided into an observation group (n =40 cases)and a control group (n =40).Both groups received neu-rosurgery routine treatment.Patients in the observation group were also treated with ganglioside sodium in addi-tion to edaravone treatment,while those in the control group used edaravone alone...Both groups received treat-ment for 2 weeks.The serum c-reactive protein (CRP),tumor necrosis factor alpha (TNF-α),calcitonin gene re-lated peptide (CGRP)and neuropeptide Y (NPY),and neuron specific enolization enzyme (NSE)levels were measured in patients from both groups 3 days,1 week,and 2 weeks before and after treatment.Results were re-corded according to the Glasgow outcome scale (GOS)3 months after treatment.[Results]In both groups,levels of serum TNF-α,CRP and NPY measured 3 days,1 week,and 2 weeks after treatment were lower than those measured before the treatment (P <0.05 ).However,levels of serum TNF alpha,CRP and NPY in 3 days,1 week,2 weeks after treatment in patients of the observation group were lower than those in the control group (P<0.05).NSE levels of patients in the observation group were significantly lower than those of the control group ( P <0.05 ).CGRP levels of patients in both groups were higher than levels before treatment (P < 0.05 ),and CGRP levels in the observation group were higher than those in the control group (P <0.05).GOS scores were measured 3 months after treatment.The prognosis in the observation group was at a good rate (90.0%)and was significantly higher than that of the control group (72.5%)(chi-square=4.021;P =4.021 ).[Conclusion]Com-bined application of Monosialoteterahexosyl Ganglioside and Edaravone can greatly reduce the serum TNF-α, CRP,and NPY levels and increase CGRP level,in addition to having good brain-protective effect and improving the prognosis rate of patients.